Kanagala, Prathap
,
Squire, Iain B.
Jones, Donald J. L.
Cao, Thong Huy
Chan, Daniel C. S.
McCann, Gerry
Sandhu, Jatinderpal K.
Quinn, Paulene A.
McAdam, John
Marsh, Anna-Marie
Davies, Joan E.
Struck, Joachim
Bergmann, Andreas
Sabti, Zaid
Twerenbold, Raphael
Herrmann, Thomas
Kozhuharov, Nikola
Mueller, Christian
Ng, Leong L.
Funding for this research was provided by:
John and Lucille Van Geest Foundation
British Heart Foundation (FS/15/10/31223)
National Institute for Health Research (GB) Leicester Biomedical Research centre
Article History
Received: 25 August 2018
Accepted: 29 January 2019
First Online: 14 February 2019
Compliance with ethical standards
:
: Dr. Bergmann holds ownership in Sphingotec GmbH which manufactures the PENK assay, and is a member of the board of directors of Sphingotec GmbH. Dr. Struck is an employee of Sphingotec GmbH which manufactures the PENK assay. Dr. Mueller has received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the European Union, the Cardiovascular Research Foundation Basel, the University Hospital Basel, Abbott, Astra Zeneca, Beckman Coulter, BG medicine, Biomerieux, BRAHMS, Critical Diagnostics, Nanosphere, Roche, Siemens, Singulex, Sphingotec, 8sense as well as speaker/consulting honoraria from Abbott, Alere, Astra Zeneca, Biomerieux, BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Eli Lilly, Novartis, Roche, Sanofi, Siemens, and Singulex. Dr Squire has received research grants from Novartis AG and Servier as well as speaker/consulting honoraria from Novartis. The authors declare that they have no conflict of interest.